ArticleNature communications2017
Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
189 citing papers in PubMed, 1 synthesis or guideline pooled it, 274 citations in OpenAlex.
- Tissue-Resident Memory T Cells in Skin Diseases: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Design and functional characterization of recombinant chimeras as vaccine candidates against Lawsonia intracellularis.Biotechnology letters · 2026Article
- Photodynamic immune stimulation eradicates primary pigmented melanoma and induces long-lasting anti-tumor immunity.British journal of cancer · 2026Article
- Spatially fractionated radiotherapy and immunotherapy: a synergistic strategy for systemic anti-tumor immunity.Journal of translational medicine · 2026Review
- CD8MedComm · 2026Review
- Enhanced mRNA vaccine combined with immune checkpoint blockade efficiently suppresses tumor growth and metastasis.Journal of nanobiotechnology · 2026Article
- Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells.The Journal of clinical investigation · 2026Article
- CD4 and CD8 T-cell lymphocytes from penile squamous cell carcinoma tumors are more differentiated with higher PD-1 expression compared to lymphocytes in peripheral circulation.Immunology letters · 2026Review
- Photoimmunological hydrogel vaccine creates a supportive immune niche to promote antigen cross-presentation cascade and cancer-immunity cycle progression.Acta pharmaceutica Sinica. B · 2026Article
- T-cell-targeted immunotherapy in neurofibromatosis type 2-related vestibular schwannoma: current evidence and future direction.Brain communications · 2026Review
- The interplay between recovery and immunity in infectious and non-communicable diseases.Frontiers in cellular and infection microbiology · 2026Review
- Tissue-Resident Memory T Cells: Pioneering New Avenues in Cancer Immunotherapy.Cancer medicine · 2025Review
- Tanshinone I Enhances the Pulmonary Immune Response of CD8Biomedicines · 2025Article
- Regulatory T cells inhibit CD8bioRxiv : the preprint server for biology · 2025Article
- CD8 T Cell Hyperfunction and Reduced Tumour Control in Murine Models of Advanced Liver Disease.European journal of immunology · 2025Article
- PD-1 is requisite for skin TNature immunology · 2025Article
- Targeting tumor-associated CCR2Science advances · 2025Article
- A scoping review on the importance of vaccination strategies targeting skin imprinting for arthropod-borne diseases.NPJ vaccines · 2025Article
- Verteporfin-Mediated In Situ Nanovaccine Based on Local Conventional-Dose Hypofractionated Radiotherapy Enhances Antitumor and Immunomodulatory Effect.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Intranodal injection of neoantigen-bearing engineeredActa pharmaceutica Sinica. B · 2025Article
129 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of successful anti-tumoural immunity is the development of long-term protective immunity to prevent relapse. Infiltration of tumours with CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.